ABOS Stock Acumen Pharmaceuticals (ABOS, $2.02) entered Downtrend as Momentum indicator drops below 0 level on Jan 02, 2026
at Tickeron.com
This indicator may be signaling that ABOS's price has further to drop, since it fell below its price logged 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options. A.I.dvisor backtested 86 similar cases where ABOS's Momentum Indicator fell below the 0 level, and of them led to a successful outcome. Odds of Success:
ABOS sees MACD Histogram crosses below signal line
ABOS saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on December 30, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 38 instances where the indicator turned negative. In of the 38 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on January 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABOS as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
ABOS moved below its 50-day moving average on January 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ABOS crossed bearishly below the 50-day moving average on January 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABOS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ABOS advanced for three days, in of 227 cases, the price rose further within the following month. The odds of a continued upward trend are .
ABOS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 138 cases where ABOS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ABOS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.164) is normal, around the industry mean (30.106). P/E Ratio (0.000) is within average values for comparable stocks, (51.324). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.888). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (322.270).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABOS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Advertisement
General Information
Industry Biotechnology